Cargando…

Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer

INTRODUCTION: The use of pre- and post-surgery variables has been used to create nomograms in order to identify patients at high risk of treatment failure. The PRIX nomogram is one such device; we compare the PRIX nomogram with the presence of secondary circulating prostate cells to predict those me...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, Nigel P, Aedo, Socrates, Fuentealba, Cynthia, Reyes, Eduardo, Jacob, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428563/
https://www.ncbi.nlm.nih.gov/pubmed/30583343
http://dx.doi.org/10.31557/APJCP.2018.19.12.3375
_version_ 1783405419250581504
author Murray, Nigel P
Aedo, Socrates
Fuentealba, Cynthia
Reyes, Eduardo
Jacob, Omar
author_facet Murray, Nigel P
Aedo, Socrates
Fuentealba, Cynthia
Reyes, Eduardo
Jacob, Omar
author_sort Murray, Nigel P
collection PubMed
description INTRODUCTION: The use of pre- and post-surgery variables has been used to create nomograms in order to identify patients at high risk of treatment failure. The PRIX nomogram is one such device; we compare the PRIX nomogram with the presence of secondary circulating prostate cells to predict those men who will undergo treatment failure. METHODS AND PATIENTS: Men who underwent radical prostatectomy for prostate cancer entered the study. The PRIX score was calculated from the total serum PSA pre-surgery, the biopsy Gleason score and clinical stage. Circulating prostate cells were detected from venous blood one month after surgery, using differential gel centrifugation and standard immunocytochemistry with anti-PSA. A test was considered positive when 1 CPC/blood sample was detected. Patients were followed up for five years and biochemical failure was defined as a serum PSA >0.2ng/ml. Kaplan-Meier and Cox proportional models were used to calculate survival curves. RESULTS: 321 men participated, of whom 131 (40.8%) underwent biochemical failure within 5 years. A higher PRIX score was associated with increased failure risk, as was the presence of CPCs. The predictive power of CPCs was significantly higher than the PRIX score. Combining the two methods, for equal PRIX scores, scores but CPC positive had a worse biochemical failure free survival than men with high PRIX scores but CPC negative. For men with PRIX scores of ≥4 the use of CPC detection did not aid in the clinical decision making process. For those with PRIX scores of 0 and 1, CPC detection identified men with a high risk of treatment failure. CONCLUSIONS: The combined PRIX/CPC score improved the predictive values of men at high risk of biochemical failure. Both are simple systems that could be incorporated in a general hospital. Further multicenter studies are warranted to confirm these results.
format Online
Article
Text
id pubmed-6428563
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-64285632019-04-01 Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer Murray, Nigel P Aedo, Socrates Fuentealba, Cynthia Reyes, Eduardo Jacob, Omar Asian Pac J Cancer Prev Research Article INTRODUCTION: The use of pre- and post-surgery variables has been used to create nomograms in order to identify patients at high risk of treatment failure. The PRIX nomogram is one such device; we compare the PRIX nomogram with the presence of secondary circulating prostate cells to predict those men who will undergo treatment failure. METHODS AND PATIENTS: Men who underwent radical prostatectomy for prostate cancer entered the study. The PRIX score was calculated from the total serum PSA pre-surgery, the biopsy Gleason score and clinical stage. Circulating prostate cells were detected from venous blood one month after surgery, using differential gel centrifugation and standard immunocytochemistry with anti-PSA. A test was considered positive when 1 CPC/blood sample was detected. Patients were followed up for five years and biochemical failure was defined as a serum PSA >0.2ng/ml. Kaplan-Meier and Cox proportional models were used to calculate survival curves. RESULTS: 321 men participated, of whom 131 (40.8%) underwent biochemical failure within 5 years. A higher PRIX score was associated with increased failure risk, as was the presence of CPCs. The predictive power of CPCs was significantly higher than the PRIX score. Combining the two methods, for equal PRIX scores, scores but CPC positive had a worse biochemical failure free survival than men with high PRIX scores but CPC negative. For men with PRIX scores of ≥4 the use of CPC detection did not aid in the clinical decision making process. For those with PRIX scores of 0 and 1, CPC detection identified men with a high risk of treatment failure. CONCLUSIONS: The combined PRIX/CPC score improved the predictive values of men at high risk of biochemical failure. Both are simple systems that could be incorporated in a general hospital. Further multicenter studies are warranted to confirm these results. West Asia Organization for Cancer Prevention 2018 /pmc/articles/PMC6428563/ /pubmed/30583343 http://dx.doi.org/10.31557/APJCP.2018.19.12.3375 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
Murray, Nigel P
Aedo, Socrates
Fuentealba, Cynthia
Reyes, Eduardo
Jacob, Omar
Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer
title Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer
title_full Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer
title_fullStr Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer
title_full_unstemmed Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer
title_short Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer
title_sort combining the prostate cancer risk index (prix) with the presence of secondary circulating prostate cells to predict the risk of biochemical failure after radical prostatectomy for prostate cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428563/
https://www.ncbi.nlm.nih.gov/pubmed/30583343
http://dx.doi.org/10.31557/APJCP.2018.19.12.3375
work_keys_str_mv AT murraynigelp combiningtheprostatecancerriskindexprixwiththepresenceofsecondarycirculatingprostatecellstopredicttheriskofbiochemicalfailureafterradicalprostatectomyforprostatecancer
AT aedosocrates combiningtheprostatecancerriskindexprixwiththepresenceofsecondarycirculatingprostatecellstopredicttheriskofbiochemicalfailureafterradicalprostatectomyforprostatecancer
AT fuentealbacynthia combiningtheprostatecancerriskindexprixwiththepresenceofsecondarycirculatingprostatecellstopredicttheriskofbiochemicalfailureafterradicalprostatectomyforprostatecancer
AT reyeseduardo combiningtheprostatecancerriskindexprixwiththepresenceofsecondarycirculatingprostatecellstopredicttheriskofbiochemicalfailureafterradicalprostatectomyforprostatecancer
AT jacobomar combiningtheprostatecancerriskindexprixwiththepresenceofsecondarycirculatingprostatecellstopredicttheriskofbiochemicalfailureafterradicalprostatectomyforprostatecancer